ReviewAmerican journal of preventive medicine2022
Pharmacist Interventions for Medication Adherence: Community Guide Economic Reviews for Cardiovascular Disease.
Review in American journal of preventive medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 23 citations in OpenAlex.
- Community Guide Methods for Systematic Reviews of Economic Evidence.American journal of preventive medicine · 2023Pooled it
- Mapping medication adherence interventions across Europe: Expert perspectives from 35 countries.Public health in practice (Oxford, England) · 2026Article
- Clinical pharmacists' aspirations on prescribing in cardiology within an academic health system.Exploratory research in clinical and social pharmacy · 2026Article
- Lifetime Effects of Adherence to Cardiovascular and Diabetes Medications in Spain: A Modelling Study in a Population Cohort of 152,117 Patients.PharmacoEconomics · 2026Article
- Adherence to guideline-directed medical treatments in heart failure. A scientific statement of the Heart Failure Association (HFA) of the ESC and the ESC Working Group on Cardiovascular Pharmacotherapy.European journal of heart failure · 2025Review
- Impact of a pharmacy care management service on cardiometabolic medication adherence and resource use for Medicare Advantage beneficiaries.Journal of managed care & specialty pharmacy · 2025Article
- Effectiveness of Pharmacist-Led Intervention on Medication Adherence in Chronic Diseases: A Systematic Review of Randomized Controlled Trials.Patient preference and adherence · 2025Review
- Patterns and predictors of self-medication behavior of weight loss medications: a cross-sectional analysis of social media influence and role of pharmacist intervention.Frontiers in pharmacology · 2025Article
- Sex-based disparities with cost-related medication adherence issues in patients with hypertension, ischemic heart disease, and heart failure.Journal of the American Medical Informatics Association : JAMIA · 2024Article
- Antihypertensive Medication Adherence and Medical Costs, Health Care Use, and Labor Productivity Among People With Hypertension.Journal of the American Heart Association · 2024Article
- Improving medication adherence in cardiovascular disease.Nature reviews. Cardiology · 2024Review
- [Design of a Tool for Patient Classification Based on Pharmacotherapeutic Attitudes].Farmaceuticos comunitarios · 2024Observational
- Pharmacokinetic Study and Metabolite Identification of 1-(3'-bromophenyl)-heliamine in Rats.Pharmaceuticals (Basel, Switzerland) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 5 institutions in 1 country.
Funding
Abstract
introductionAdherence to medications for cardiovascular disease and its risk factors is less than optimal, although greater adherence to medication has been shown to reduce the risk factors for cardiovascular disease. This paper examines the economics of tailored pharmacy interventions to improve medication adherence for cardiovascular disease prevention and management.
methodsLiterature from inception of databases to May 2019 was searched, yielding 29 studies for cardiovascular disease prevention and 9 studies for cardiovascular disease management. Analyses were done from June 2019 through May 2020. All monetary values are in 2019 U.S. dollars.
resultsThe median intervention cost per patient per year was $246 for cardiovascular disease prevention and $292 for cardiovascular disease management. The median change in healthcare cost per person per year due to the intervention was -$355 for cardiovascular disease prevention and -$2,430 for cardiovascular disease management. The median total cost per person per year was -$89 for cardiovascular disease prevention, with a median return on investment of 0.01. The median total cost per person per year for cardiovascular disease management was -$1,080, with a median return on investment of 7.52, and 6 of 7 estimates indicating reduced healthcare cost averted exceeded intervention cost. For cardiovascular disease prevention, the median cost per quality-adjusted life year gained was $11,298. There were no cost effectiveness studies for cardiovascular disease management. DISCUSSION: The evidence shows that tailored pharmacy-based interventions to improve medication adherence are cost effective for cardiovascular disease prevention. For cardiovascular disease management, healthcare cost averted exceeds the cost of implementation for a favorable return on investment from a healthcare systems perspective.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.